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DOI 10.1016/j.ccr.2010.03.017SUMMARYWe have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the context of
istinct subset of samples displays concerted hyperme-The Cancer Genome Atlas (TCGA). We found that a dthylation at a large number of loci, indicating the existence of a glioma-CpG island methylator phenotype
(G-CIMP). We validated G-CIMP in a set of non-TCGA glioblastomas and low-grade gliomas. G-CIMP tumors
belong to the proneural subgroup, are more prevalent among lower-grade gliomas, display distinct copy-
number alterations, and are tightly associated with IDH1 somatic mutations. Patients with G-CIMP tumors
are younger at the time of diagnosis and experience significantly improved outcome. These findings identify
G-CIMP as a distinct subset of human gliomas on molecular and clinical grounds.
INTRODUCTION
Human gliomas present as heterogeneous disease, primarily
itively been identified, however, the identification of tumorigenic,
stem-cell like precursor cells in advanced stage gliomas
suggests that human gliomas may have a neural stem cell origindefined by the histologic appearance of the tumor cells. Astrocy-
toma and oligodendroglioma constitute the infiltrating gliomas
(Adamson et al., 2009). The cell or cells of origin have not defin-Significance
Glioblastoma (GBM) is a highly aggressive form of brain tumo
Cancer Genome Atlas (TCGA) project aims to characterize can
tion, detection, and therapy. Using TCGA data, we identified
methylation alterations, referred to as a glioma CpG island me
molecular features, including a high frequency of IDH1mutatio
G-CIMP tumors are younger at diagnosis and display improved
define a distinct subset of human gliomas with specific clinica
510 Cancer Cell 17, 510–522, May 18, 2010 ª2010 Elsevier Inc.(Canoll and Goldman, 2008; Dirks, 2006; Galli et al., 2004).
Gliomas are subdivided by the World Health Organization
(WHO) by histological grade, which is an indication ofr, with a patient median survival of just over one year. The
cer genomes to identify means of improving cancer preven-
a subset of GBM tumors with characteristic promoter DNA
thylator phenotype (G-CIMP). G-CIMP tumors have distinct
n and characteristic copy-number alterations. Patients with
survival times. The molecular alterations in G-CIMP tumors
l features.
differentiation status, malignant potential, response to treat-
ment, and survival. Glioblastoma (GBM), also described as
grade IV glioma, accounts for more than 50% of all gliomas
(Adamson et al., 2009). Patients with GBM have an overall
acterized by tumors in the proximal colon, a tight association
with BRAF mutations, and microsatellite instability caused by
MLH1 promoter hypermethylation and transcriptional silencing
(Weisenberger et al., 2006).
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CpG Island Methylator Phenotype in Gliomasmedian survival time of only 15 months (Brandes et al., 2001;
Martinez et al., 2010; Parsons et al., 2008). Most GBMs are diag-
nosed as de novo or primary tumors and are more common in
males. A subset of 5% of GBM tumors, termed secondary
GBM, progress from lower-grade tumors (grade II/III), are seen
in younger patients, are more evenly distributed among the
sexes, and exhibit longer survival times (reviewed in Adamson
et al., 2009; Furnari et al., 2007).
There is currently great interest in characterizing and
compiling the genome and transcriptome changes in human
GBM tumors to identify aberrantly functioning molecular path-
ways and tumor subtypes. The Cancer Genome Atlas (TCGA)
pilot project identified genetic changes of primary DNA
sequence and copy number, DNAmethylation, gene expression,
and patient clinical information for a set of GBM tumors (The
Cancer Genome Atlas Research Network, 2008). TCGA also
reaffirmed genetic alterations in TP53, PTEN, EGFR, RB1 NF1,
ERBB2, PIK3R1, and PIK3CA mutations and detected an
increased frequency of NF1 mutations in GBM patients (The
Cancer Genome Atlas Research Network, 2008). Recent DNA
sequencing analyses of primary GBM tumors with a more
comprehensive approach (Parsons et al., 2008) also identified
somatic mutations in isocitrate dehydrogenase 1 (IDH1) that
occur in 12% of all GBM patients. IDH1 mutations have only
been detected at the arginine residue in codon 132, with the
most common change being the R132H mutation (Parsons
et al., 2008; Yan et al., 2009), which results in a gain of enzyme
function in directly catalyzing a-ketoglutarate to R(-)-2-hydroxy-
glutarate (Dang et al., 2009). IDH1 mutations are enriched in
secondary GBM cases and younger individuals and are coinci-
dent with increased patient survival (Balss et al., 2008; Hartmann
et al., 2009; Yan et al., 2009). Higher IDH1 mutation rates are
seen in grade II and III astrocytomas and oligodendrogliomas
(Balss et al., 2008; Bleeker et al., 2009; Hartmann et al., 2009;
Yan et al., 2009), suggesting that IDH1mutations generally occur
in the progressive form of glioma, rather than in de novo GBM.
Mutations in the related IDH2 gene are of lower frequency and
generally nonoverlapping with tumors containing IDH1 muta-
tions (Hartmann et al., 2009; Yan et al., 2009).
Cancer-specific DNA methylation changes are hallmarks of
human cancers, in which global DNA hypomethylation is
often seen concomitantly with hypermethylation of CpG islands
(reviewed in Jones and Baylin, 2007). Promoter CpG island
hypermethylation generally results in transcriptional silencing
of the associated gene (Jones and Baylin, 2007). CpG island
hypermethylation events have also been shown to serve as
biomarkers in human cancers, for early detection in blood and
other bodily fluids, for prognosis or prediction of response to
therapy, and to monitor cancer recurrence (Laird, 2003).
A CpG island methylator phenotype (CIMP) was first charac-
terized in human colorectal cancer by Toyota and colleagues
(Toyota et al., 1999) as cancer-specific CpG island hypermethy-
lation of a subset of genes in a subset of tumors. We confirmed
and further characterized colorectal CIMP using MethyLight
technology (Weisenberger et al., 2006). Colorectal CIMP is char-DNA methylation alterations have been widely reported in
human gliomas, and there have been several reports of pro-
moter-associated CpG island hypermethylation in human GBM
and other glioma subtypes (Kim et al., 2006; Martinez et al.,
2009; Martinez et al., 2007; Nagarajan and Costello, 2009; Stone
et al., 2004; Tepel et al., 2008; Uhlmann et al., 2003). Several
studies have noted differences between primary and secondary
GBMs with respect to epigenetic changes. Overall, secondary
GBMs have a higher frequency of promoter methylation than
primary GBM (Ohgaki and Kleihues, 2007). In particular,
promoter methylation of RB1 was found to be approximately
three times more common in secondary GBM (Nakamura
et al., 2001).
Hypermethylation of the MGMT promoter-associated CpG
island has been shown in a large percentage of GBM patients
(Esteller et al., 2000; Esteller et al., 1999; Hegi et al., 2005; Hegi
et al., 2008; Herman and Baylin, 2003). MGMT encodes for an
O6-methylguanine methyltransferase that removes alkyl groups
from the O-6 position of guanine. GBM patients with MGMT
hypermethylation showed sensitivity to alkyating agents such
as temozolomide, with an accompanying improved outcome
(Esteller et al., 2000; Esteller et al., 1999; Hegi et al., 2005; Hegi
et al., 2008; Herman and Baylin, 2003). However, initial promoter
methylation of MGMT, in conjunction with temozolomide treat-
ment, may result in selective pressure to lose mismatch repair
function, resulting inaggressive recurrent tumorswithahypermu-
tator phenotype (Cahill et al., 2007; Hegi et al., 2005; Silber et al.,
1999; The Cancer Genome Atlas Research Network, 2008).
Here, we report the DNA methylation analysis of 272 GBM
tumors collected for TCGA, extend this to lower-grade tumors,
and characterize a distinct subgroup of human gliomas exhibit-
ing CIMP.
RESULTS
Identification of a Distinct DNA Methylation Subgroup
within GBM Patients
We determined DNA methylation profiles in a discovery set of
272 TCGA GBM samples. At the start of this study, we relied
on the Illumina GoldenGate platform, using both the standard
Cancer Panel I, and a custom-designed array (The Cancer
Genome Atlas Research Network, 2008) (Figures S1A–S1C
available online and Experimental Procedures), but migrated to
the more comprehensive Infinium platform (Figure 1 and
Figure S1C), as it became available. DNA methylation measure-
ments were highly correlated for CpG dinucleotides shared
between the two platforms (Pearson’s r = 0.94, Figure S1D).
Both platforms interrogate a sampling of about twoCpGdinucle-
otides per gene. Although this implies that nonrepresentative
CpGs may be assessed for some promoters, it is likely that
representative results will be obtained for most gene promoters,
given the very high degree of locally correlated DNA methylation
behavior (Eckhardt et al., 2006).
We selected the most variant probes on each platform and
performed consensus clustering to identify GBM subgroups
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(Monti et al., 2003). We identified three DNAmethylation clusters
using either the GoldenGate or Infinium data, with 97% concor-
dance (61/63) in cluster membership calls for samples run on
both platforms (Table S1). Cluster 1 formed a particularly tight
ized with TCGA GBM samples (Verhaak et al., 2010). We
compared the DNA methylation consensus cluster assignments
for each sample to their gene expression cluster assignments
(Figure 1, Figure 2A, Figures S1A and S1B, and Table S1). The
A B
Figure 1. Clustering of TCGA GBM Tumors and Control Samples Identifies a CpG Island Methylator Phenotype
Unsupervised consensus clustering was performed with the 1503 Infinium DNA methylation probes whose DNA methylation beta values varied the most across
the 91 TCGA GBM samples. DNA methylation clusters are distinguished with a color code at the top of the panel: red, consensus cluster 1 (n = 12 tumors); blue,
consensus cluster 2 (n = 31 tumors); and green, consensus cluster 3 (n = 48 samples). Each sample within each DNA Methylation cluster are color labeled as
described in the key for its gene expression cluster membership (proneural, neural, classical, and mesenchymal). The somatic mutation status of five genes
(EGFR, IDH1,NF1, PTEN, and TP53) are indicated by the black squares, the gray squares indicate the absence of mutations in the sample, and the white squares
indicate that the gene was not screened in the specific sample. G-CIMP-positive samples are labeled at the bottom of the matrix.
(A) Consensus matrix produced by k-means clustering (K = 3). The samples are listed in the same order on the x and y axes. Consensus index values range from
0 to 1, with 0 being highly dissimilar and 1 being highly similar.
(B) One-dimensional hierarchical clustering of the same 1503most variant probes, with retention of the same sample order as in (A). Each row represents a probe;
each column represents a sample. The level of DNA methylation (beta value) for each probe, in each sample, is represented with a color scale as shown in the
legend; white indicates missing data. M.SssI-treated DNA (n = 2), WGA-DNA (n = 2), and normal brain (n = 4) samples are included in the heatmap but did not
contribute to the unsupervised clustering. The probes in the eight control samples are listed in the same order as the y axis of the GBM sample heatmap. See also
Figure S1 and Table S1.
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ylation profile (Figure 1 and Figure S1), reminiscent of the CpG
island methylator phenotype described in colorectal cancer
(Toyota et al., 1999; Weisenberger et al., 2006). CIMP in colo-
rectal cancer is characterized by correlated cancer-specific
CpG island hypermethylation of a subset of genes in a subset
of tumors and not just a stochastic increase in the frequency of
generic CpG island methylation across the genome (Toyota
et al., 1999; Weisenberger et al., 2006). Cluster 1 GBM samples
show similar concerted methylation changes at a subset of loci.
We therefore designated cluster 1 tumors as having a glioma
CpG island methylator phenotype (G-CIMP). Combining Infinium
and GoldenGate data, we identified 24 of 272 TCGA GBM
samples (8.8%) as the G-CIMP subtype (Table S1).
Characterization of G-CIMP Tumors
within Gene Expression Clusters
Four gene expression subtypes (proneural, neural, classical, and
mesenchymal) have been previously identified and character-
512 Cancer Cell 17, 510–522, May 18, 2010 ª2010 Elsevier Inc.G-CIMP sample cluster is highly enriched for proneural GBM
tumors, whereas the DNA methylation clusters 2 and 3 are
moderately enriched for classical and mesenchymal expression
groups, respectively. Of the 24 G-CIMP tumors, 21 (87.5%) were
classified within the proneural expression group. These G-CIMP
tumors represent 30% (21/71) of all proneural GBM tumors,
suggesting that G-CIMP tumors represent a distinct subset of
proneural GBM tumors (Figure 2A, Figure S2A, and Table S1).
The few nonproneural G-CIMP tumors belong to neural (2/24
tumors, 8.3%), and mesenchymal (1/24 tumors, 4.2%) gene
expression groups.
In order to obtain an integrated view of the relationships of
G-CIMP status and gene expression differences, we performed
pairwise comparisons between members of different molecular
subgroups (Figure 2B). We calculated the mean Euclidean
distance in both DNA methylation and expression for each
possible pairwise combination of the five different subtypes:
G-CIMP-positive proneural, G-CIMP-negative proneural, clas-
sical, mesenchymal, and neural tumors. We observed the high
dissimilarity of the GP, GN, GC, and GM pairs (Figure 2B), sup-
porting the hypothesis that G-CIMP-positive tumors are a unique
molecular subgroup of GBM tumors and more specifically that
G-CIMP status provides further refinement of the proneural
Clinical Characterization of G-CIMP Tumors
We further characterized G-CIMP tumors by reviewing the
available clinical covariates for each patient. Although patients
with proneural GBM tumors are slightly younger (median age,
A D
EB
C F
Figure 2. Characterization of G-CIMP
Tumors as aUnique Subtype of GBMswithin
the Proneural Gene Expression Subgroup
(A) Integration of the samples within each DNA
methylation and gene expression cluster. Samples
are primarily categorized by their gene expression
subtype: P, proneural; N, neural; C, classical; and
M, mesenchymal. The number and percent of
tumors within each DNA methylation cluster (red,
cluster 1 [G-CIMP]; blue, cluster 2; green, cluster
3) are indicated for each gene expression subtype.
(B) Scatter plot of pairwise comparison of the gene
expression and DNA methylation clusters as iden-
tified in Figure 1 and Figure S1. Same two-letter
represents self-comparison, whereas mixed two-
letter represents the pairwise correlation between
gene expression and DNA methylation. Axes are
reversed to illustrate increasing similarity.
(C) GBM patient age distribution at time of
diagnosis within each gene expression cluster.
Samples are divided by gene expression clusters
as identified along the top of each jitter plot and
further subdivided by G-CIMP status within each
expression subgroup. G-CIMP-positive samples
are indicated as red data points and G-CIMP-
negative samples are indicated as black data
points. Median age at diagnosis is indicated for
each subgroup by a horizontal solid black line.
(D–F) Kaplan-Meier survival curves for GBMmeth-
ylation and gene expression subtypes. In each
plot, the percent probability of survival is plotted
versus time since diagnosis in weeks. All samples
with survival data greater than 5 years were
censored.
(D) Kaplan-Meier survival curves among the four
GBM expression subtypes. Proneural tumors are
represented in blue, neural tumors are represented
in green, classical tumors are represented in red,
and mesenchymal tumors are represented in gold.
(E) Kaplan-Meier survival curves between the
three DNA methylation clusters. Cluster 1 tumors
are represented in red, cluster 2 tumors are repre-
sented in blue, and cluster 3 tumors are repre-
sented in green.
(F) Kaplan-Meier survival curves among proneural
G-CIMP-positive, proneural G-CIMP-negative,
and all nonproneural GBM tumors. Proneural
G-CIMP-positive tumors are represented in red,
proneural G-CIMP-negative tumors are repre-
sented in blue, and all nonproneural GBM tumors
are represented in black. See also Figure S2.
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tive tumors are distinctly dissimilar to the mesenchymal tumors
(GM pair), whereas the G-CIMP-negative proneural tumors are
relatively similar to mesenchymal tumors (PM pair). We focused
downstream analyses on comparisons between G-CIMP-
positive versus G-CIMP-negative tumors within the proneural
subset, to avoid misidentifying proneural features as G-CIMP-
associated features.56 years) than all other nonproneural GBM patients (median
age, 57.5 years), this was not statistically significant (p = 0.07).
However, patients with G-CIMP tumors were significantly
younger at the time of diagnosis compared with patients diag-
nosed with non-G-CIMP proneural tumors (median ages of 36
and 59 years, respectively; p < 0.0001; Figure 2C).
The overall survival for patients of the proneural subtype was
not significantly improved compared to other gene expression
Cancer Cell 17, 510–522, May 18, 2010 ª2010 Elsevier Inc. 513
subtypes (Figure 2D), but significant survival differences were
seen for groups defined by DNA methylation status (Figures 2E
and 2F and Figure S2B). We observed significantly better
survival for proneural G-CIMP-positive patients (median survival
diagnosis compared to patients with G-CIMP-negative, IDH1-
wild-type tumors (median ages of 37 and 59 years respectively;
p < 0.008). Interestingly, two of the five patients each survived
more than 5 years after diagnosis. We did not observe any
Table 1. G-CIMP and IDH1 Mutation Status in Primary,
Secondary, and Recurrent GBMs
G-CIMP
GBMs — + Total
All Tumors
IDH1
Wild-type 184 5 189
Mutant 0 18 18
Total 184 23 207
Primary Tumors
IDH1
Wild-type 171 4 175
Mutant 0 12 12
Total 171 16 187
Recurrent Tumors
IDH1
Wild-type 12 0 12
Mutant 0 4 4
Total 12 4 16
Secondary Tumors
IDH1
Wild-type 1 1 2
Mutant 0 2 2
Total 1 3 4
G-CIMP and IDH1 mutation status are compared for All analyzed GBM
tumors (p < 2.2 3 1016), Primary tumors, Recurrent tumors, and
Secondary tumors. P value is calculated from Fisher’s exact test. See
also Figure S3 and Table S2.
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CpG Island Methylator Phenotype in Gliomasof 150 weeks) than proneural G-CIMP-negative patients (median
survival of 42 weeks) or all other nonproneural GBM patients
(median survivals of 54weeks). G-CIMP status remained a signif-
icant predictor of improved patient survival (p = 0.0165) in Cox
multivariate analysis after adjusting for patient age, recurrent
versus non-recurrent tumor status and secondary GBM versus
primary GBM status.
IDH1 Sequence Alterations in G-CIMP Tumors
Nine genes were found to have somatic mutations that were
significantly associated with proneural G-CIMP-positive tumors
(Figure S3A and Table S2). IDH1 somatic mutations, recently
identified primarily in secondary GBM tumors (Balss et al.,
2008; Parsons et al., 2008; Yan et al., 2009), were found to be
very tightly associated with G-CIMP in our data set (Table 1),
with 18 IDH1 mutations primarily observed in 23 (78%)
G-CIMP-positive tumors, and 184 G-CIMP-negative tumors
were IDH1-wild-type (p < 2.23 1016). The five discordant cases
of G-CIMP-positive, IDH1-wild-type tumors are not significantly
different in age compared to G-CIMP-positive, IDH1 mutant
tumors (median ages of 34 and 37 years respectively; p =
0.873). However, the five discordant cases of G-CIMP-positive,
IDH1-wild-type tumors are significantly younger at the time of
514 Cancer Cell 17, 510–522, May 18, 2010 ª2010 Elsevier Inc.IDH2 mutations in the TCGA data set. Tumors displaying both
G-CIMP-positive and IDH1 mutation occurred at low frequency
in primary GBM, but were enriched in the set of 16 recurrent
(treated) tumors and to an even greater degree in the set of
four secondary GBM (Table 1). We also identified examples of
germline mutations (nine genes) and loss of heterozygosity
(six genes) that were significantly associated with proneural
G-CIMP-positive tumors (Figures S3B and S3C and Table S2).
DNA Copy-Number Variation in Proneural G-CIMP
Tumors
In order to elucidate critical alterations within proneural G-CIMP-
positive tumors, we analyzed gene-centric copy-number
variation data (see Supplemental Information). We identified
significant copy-number differences in 2875 genes between
proneural G-CIMP-positive and G-CIMP-negative tumors (Fig-
ure 3A and Table S3). Although chromosome 7 amplifications
are a hallmark of aggressive GBM tumors (The Cancer Genome
Atlas Research Network, 2008), copy-number variation along
chromosome 7 was reduced in proneural G-CIMP-positive
tumors. Gains in chromosomes 8q23.1-q24.3 and 10p15.3-
p11.21 were identified (Figures 3B and 3C). The 8q24 region
contains the MYC oncogene, is rich in sequence variants, and
was previously shown as a risk factor for several human cancers
(Amundadottir et al., 2006; Freedman et al., 2006; Haiman et al.,
2007a; Haiman et al., 2007b; Schumacher et al., 2007;
Shete et al., 2009; Visakorpi et al., 1995; Yeager et al., 2007).
Accompanying the gains at chromosome 10p in proneural
G-CIMP-positive tumors, we also detected deletions of the
same chromosome arm in G-CIMP-negative tumors (Figure 3C).
Similar copy-number variation results were obtained when
comparing all G-CIMP-positive to G-CIMP-negative samples
(Figure S4). These findings point to G-CIMP-positive tumors as
having a distinct profile of copy-number variation when
compared to G-CIMP-negative tumors.
Identification of DNA Methylation and Transcriptome
Expression Changes in Proneural G-CIMP Tumors
To better understand CpG island hypermethylation in glioblas-
toma, we investigated the differentially methylated CpG sites
of these samples (Figure 1B). Among 3153 CpG sites that were
differentially methylated between proneural G-CIMP positive
and proneural G-CIMP-negative tumors, 3098 (98%) were
hypermethylated (Figure 4A). In total, there were 1550 unique
genes, of which 1520 were hypermethylated and 30 were hypo-
methylated within their promoter regions. We ranked our probe
list by decreasing adjusted p values and increasing beta-value
difference in order to identify the topmost differentially hyperme-
thylated CpG probes within proneural G-CIMP-positive tumors
(Table S3).
The Agilent transcriptome data were used to detect genes
showing both differential expression and G-CIMP DNA methyla-
tion, in G-CIMP-positive and negative proneural samples. Gene
expression values were adjusted for regional copy number
changes, as described in Supplemental Information. A total of
1,030 genes were significantly downregulated and 654 genes
were significantly upregulated among proneural G-CIMP-posi-
tive tumors (Figure 4B and Table S3). The differentially downre-
gulated gene set was highly enriched for polysaccharide,
Integration of the normalized gene expression and DNA
methylation gene lists identified a total of 300 genes with both
significant DNA hypermethylation and gene expression changes
in G-CIMP-positive tumors compared to G-CIMP-negative
A
B C
Figure 3. Significant Regions of Copy-Number Variation in the G-CIMP Genome
Copy-number variation for 23,748 loci (across 22 autosomes and plotted in genomic coordinates along the x axis) was analyzed with 61 proneural TCGA GBM
tumors. Homozygous deletion is indicated in dark blue, hemizygous deletion is indicated in light blue, neutral/no change is indicated in white, gain is indicated in
light red, and high-level amplification is indicated in dark red.
(A) Copy-number variation between proneural G-CIMP positive and G-CIMP negative tumors. The Cochran Armitage test for trend, percent total amplification/
deletion, and raw copy-number values are listed. The –log10(FDR-adjusted p value) between G-CIMP-positive and G-CIMP negative proneurals is plotted along
the y axis in the ‘‘adjusted p value pos vs. neg’’ panel. In this panel, red vertical lines indicate significance. Gene regions in 8q23.1-q24.3 and 10p15.2-11.21 are
identified by asterisks and are highlighted in (B) and (C), respectively. See also Figure S4 and Table S3.
Cancer Cell
CpG Island Methylator Phenotype in Gliomasheparin and glycosaminoglycan binding, collagen, thrombo-
spondin, and cell morphogenesis (p < 2.2E-04, Table S3). In
addition, the significantly upregulated gene set was highly en-
riched among functional categories involved in regulation of
transcription, nucleic acid synthesis, metabolic processes, and
cadherin-based cell adhesion (p < 6.2E-04). Zinc finger tran-
scription factors were also found to be highly enriched in genes
significantly upregulated in expression (p = 3.1E-08). Similar
findings were obtained when a permutation analysis was per-
formed and when Affymetrix gene expression data were used
(data not shown). We also identified 20 miRNAs that showed
significant differences in their gene expression between proneu-
ral G-CIMP-positive and proneural G-CIMP-negative tumors
(Figure S5 and Table S3).tumors within the proneural subset. Of these, 263 were signifi-
cantly downregulated and hypermethylated within proneural
G-CIMP-positive tumors (Figure 4C, lower-right quadrant). To
validate these differentially expressed and methylated genes,
we replicated the analysis using an alternate expression platform
(Affymetrix) and derived consistent results (Figure S5). Among
the top ranked genes were FABP5, PDPN,CHI3L1, and LGALS3
(Table 2), which were identified in an independent analysis to be
highly prognostic in GBMwith higher expression associated with
worse outcome (Colman et al., 2010). Gene ontology analyses
showed G-CIMP-specific downregulation of genes associated
with themesenchyme subtype, tumor invasion, and the extracel-
lular matrix as the most significant terms (Table S3). Genes
with roles in transcriptional silencing, chromatin structure
Cancer Cell 17, 510–522, May 18, 2010 ª2010 Elsevier Inc. 515
modifications, and activation of cellular metabolic processes
showed increased gene expression in proneural G-CIMP-posi-
tive tumors. Additional genes differentially expressed in proneu-
ral G-CIMP-positive samples are provided in Table S3.
A
C
B Figure 4. Comparison of Transcriptome
versus Epigenetic Differences between
Proneural G-CIMP-Positive and G-CIMP-
Negative Tumors
(A) Volcano plots of all CpG loci analyzed for
G-CIMP association. The beta value difference
in DNA methylation between the proneural
G-CIMP-positive and proneural G-CIMP-negative
tumors is plotted on the x axis, and the p value
for a FDR-corrected Wilcoxon signed-rank test of
differences between the proneural G-CIMP-posi-
tive and proneural G-CIMP-negative tumors
(1* log10 scale) is plotted on the y axis. Probes
that are significantly different between the two
subtypes are shown in red.
(B) Volcano plot for all genes analyzed on the
Agilent gene expression platform.
(C) Starburst plot for comparison of TCGA Infinium
DNA methylation and Agilent gene expression
data normalized by copy-number information
for 11,984 unique genes. Log10(FDR-adjusted
p value) is plotted for DNA methylation (x axis)
and gene expression (y axis) for each gene. If a
mean DNA methylation b-value or mean gene
expression value is higher (greater than zero) in
G-CIMP-positive tumors, 1 is multiplied to
log10(FDR-adjusted p value), providing positive
values. The dashed black lines indicate the FDR-
adjusted p value at 0.05. Data points in red indicate
those that are significantly up- and downregulated
in their gene expression levels and significantly
hypo- or hypermethylated in proneural G-CIMP-
positive tumors. Data points in green indicate
genes that are significantly downregulated in their
gene expression levels and hypermethylated in
proneural G-CIMP-positive tumors compared to
proneural G-CIMP-negative tumors. See also
Figure S5 and Table S3.
gene expression values in a collection of
Affymetrix profiling data from published
and publicly available sources on which
clinical annotation was available. This
data were used to de
set, the expression of
ated with patient outco
suggest that G-CIMP-
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silenced genes to a NextBio (www.nextbio.com) meta-analysis
to identify data sets that were significantly associated with our
list of 263 hypermethylated and downregulated genes. There
was an overlap with downregulated genes in low- and interme-
diate-grade glioma compared to GBM in a variety of previously
published data sets (Ducray et al., 2008; Liang et al., 2005;
Sun et al., 2006) (Figure S5 and Table S3). The overlap of the
263-gene set with each of these additional datasets was unlikely
to be due to chance (all analyses p < 0.00001). To further charac-
terize this gene set, we tested the survival association of these
516 Cancer Cell 17, 510–522, May 18, 2010 ª2010 Elsevier Inc.data set included cohorts from the
Rembrandt set (Madhavan et al., 2009)
as well as other sources and did not
include TCGA data (given that TCGA
rive the gene list). In this combined data
the 263 gene set was significantly associ-
me (Figure S5G). Together, these findings
positive GBMs tumors have epigeneticallyrelated gene expression differences, which are more consistent
with low-grade gliomas as well as high-grade tumors with
favorable prognosis.
Validation of G-CIMP in GBM and Incidence
in Lower-Grade Gliomas
To validate the existence of G-CIMP loci and better characterize
the frequency of G-CIMP in gliomas, we used MethyLight to
assay the DNA methylation levels in eight G-CIMP gene regions
in seven hypermethylated loci (ANKRD43, HFE, MAL, LGALS3,
FAS-1, FAS-2, and RHO-F) and one hypomethlyated locus,
DOCK5, in the tumor samples. These eight markers were evalu-
ated in paraffin-embedded tissues from 20 TCGA samples of
known G-CIMP status (ten G-CIMP-positive and ten G-CIMP-
negative). We observed perfect concordance between G-CIMP
Table 2. The Top-50 Most Differentially Hypermethylated and
Downregulated Genes in Proneural G-CIMP-Positive Tumors
DNA Methylation Gene Expression
Gene Name
Wilcoxon
Rank
p Value
Beta Value
Difference
Wilcoxon
Rank
p Value
Fold
Change
G0S2 2.37E-07 0.76 2.12E-13 3.92
RBP1 2.37E-07 0.84 1.07E-14 3.9
FABP5 2.30E-05 0.3 1.39E-12 3.53
CA3 4.50E-06 0.43 2.06E-06 2.82
RARRES2 4.74E-07 0.63 6.25E-10 2.69
OCIAD2 2.06E-04 0.32 1.23E-08 2.64
CBR1 3.30E-05 0.37 3.77E-09 2.45
PDPN 3.87E-03 0.23 1.47E-07 2.43
LGALS3 2.37E-07 0.72 7.97E-09 2.42
CTHRC1 3.50E-04 0.45 1.44E-07 2.34
CCNA1 4.66E-03 0.29 2.95E-05 2.14
ARMC3 1.76E-03 0.31 7.76E-05 2.13
CHST6 5.74E-04 0.22 8.70E-06 2.11
C11orf63 2.37E-07 0.64 7.95E-11 2.05
GJB2 2.16E-03 0.24 2.94E-07 2.04
KIAA0746 1.66E-06 0.58 2.97E-07 1.94
MOSC2 2.37E-07 0.66 6.85E-12 1.91
CHI3L1 7.11E-06 0.13 4.11E-06 1.9
RARRES1 6.38E-05 0.41 5.93E-09 1.89
AQP5 4.50E-06 0.43 6.86E-14 1.87
SPON2 8.68E-05 0.3 2.50E-05 1.87
RAB36 2.06E-04 0.26 6.49E-11 1.86
CHRDL2 2.64E-03 0.07 1.15E-07 1.81
TOM1L1 2.37E-07 0.66 4.57E-14 1.8
BIRC3 2.37E-07 0.66 6.50E-07 1.78
LDHA 4.50E-04 0.55 1.83E-07 1.74
SEMA3E 2.37E-07 0.52 2.36E-04 1.72
FMOD 6.38E-05 0.42 2.05E-04 1.72
C10orf107 1.59E-05 0.63 4.11E-06 1.71
FLNC 2.37E-07 0.74 1.36E-05 1.67
TMEM22 4.74E-07 0.59 1.63E-08 1.67
TCTEX1D1 1.66E-06 0.37 2.97E-07 1.67
DKFZP586H2123 1.59E-05 0.53 4.83E-05 1.66
TRIP4 4.74E-07 0.49 4.18E-08 1.65
SLC39A12 1.81E-03 0.2 7.24E-06 1.65
FLJ21963 4.60E-05 0.26 8.07E-07 1.63
CRYGD 4.74E-07 0.54 2.81E-08 1.62
LECT1 5.74E-04 0.32 3.73E-07 1.61
EPHX2 2.37E-07 0.53 3.73E-06 1.6
LGALS8 3.20E-03 0.19 4.15E-13 1.6
C7orf46 2.37E-07 0.35 4.11E-06 1.58
F3 2.37E-07 0.62 4.76E-08 1.57
TTC12 9.48E-07 0.53 4.52E-06 1.57
ITGBL1 1.42E-03 0.2 1.86E-07 1.57
B3GNT5 1.66E-06 0.66 2.36E-07 1.55
NMNAT3 2.30E-05 0.62 5.93E-09 1.55
Table 2. Continued
DNA Methylation Gene Expression
Gene Name
Wilcoxon
Rank
p Value
Beta Value
Difference
Wilcoxon
Rank
p Value
Fold
Change
FZD6 6.38E-05 0.34 2.28E-06 1.55
FKBP5 9.16E-04 0.23 9.22E-09 1.54
SLC25A20 1.56E-04 0.6 1.41E-08 1.53
MMP9 2.06E-04 0.37 2.09E-03 1.53
Genes are sorted by decreasing Gene Expression log2 ratios. Beta value
difference indicates differences in mean of beta values (DNA methylation
values) between proneural G-CIMP-positive and proneural G-CIMP-
negative tumors. Fold change is the log2 ratio of the means of proneural
G-CIMP-positive and proneural G-CIMP-negative normalized expression
intensities. See also Table S3.
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markers, providing validation of the technical performance
of the platforms and of the diagnostic marker panel. These
20 samples were excluded from the validation set described
below. A sample was considered G-CIMP positive if at least
six genes displayed a combination of DOCK5 DNA hypomethy-
lation and/or hypermethylation of the remaining genes in the
panel. Using these criteria, we tested an independent set of
non-TCGA GBM samples for G-CIMP status. Sixteen of 208
tumors (7.6%) were found to be G-CIMP positive (Figure 5A),
very similar to the findings in TCGA data.
To further expand these observations, we determined the
IDH1 mutation status for an independent set 100 gliomas
(WHO grades II, III, and IV). Among 48 IDH1 mutant tumors, 35
(72.9%) were positive for G-CIMP. However, only 3/52 cases
(5.8%) without an IDH1 mutation were G-CIMP positive (odds
ratio = 42; 95% confidence interval (CI), 11-244; Figure S3D),
validating the tight association of G-CIMP and IDH1 mutation.
On the basis of the association of G-CIMP status with features
of the progressive, rather than the de novo GBM pathway, we
hypothesized that G-CIMP status was more common in the
low- and intermediate-grade gliomas. We extended this analysis
by evaluating 60 grade II and 92 grade III gliomas for G-CIMP
DNA methylation using the eight gene MethyLight panel.
Compared to GBM, grade II tumors showed a10-fold increase
in G-CIMP-positive tumors, whereas grade III tumors had an
intermediate proportion of tumors that were G-CIMP positive
(Figure 5A and Figure S3E). When low- and intermediate-grade
gliomas were separated by histologic type, G-CIMP positivity
appeared to be approximately twice as common in oligodendro-
gliomas (52/56, 93%) as compared to astrocytomas (43/95,
45%). G-CIMP positive status correlated with improved patient
survival within each WHO-recognized grade of diffuse glioma,
indicating that the G-CIMP status was prognostic for glioma
patient survival (p < 0.032, Figure 5B). G-CIMP status was an
independent predictor (p < 0.01) of survival after adjustment
for patient age and tumor grade (Figure S3F). Together, these
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findings show that G-CIMP is a prevalent molecular signature
in low-grade gliomas and confers improved survival in these
tumors.
Stability of G-CIMP at Recurrence
Because epigenetic events can be dynamic processes, we
examined whether G-CIMP status was a stable event in glioma
or whether it was subject to change over the course of the
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Figure 5. G-CIMP Prevalence in Grade II, III, and IV Gliomas with
MethyLight
(A) Methylation profiling of gliomas shows an association of CIMP status with
tumor grade. Eight markers were tested for G-CIMP DNA methylation in
360 tumor samples. Each marker was coded as red if methylated and green
if unmethylated. One of these markers (DOCK5) is unmethylated in CIMP,
whereas the remaining seven markers show G-CIMP-specific hypermethyla-
tion. G-CIMP-positive status was determined if R6 of the 8 genes had
G-CIMP-defining hyper- or hypomethylation. G-CIMP-positive status is
indicated with a black line (right side of panel), and a gray line indicates non-
G-CIMP. Samples with an identified IDH1mutation are indicated by black lines
and samples with no known IDH1 mutation are indicated by gray lines. White
lines indicate samples with unknown IDH1 status.
(B) Association of G-CIMP status with patient outcome stratified by tumor
grade. G-CIMP-positive cases are indicated by red lines and the G-CIMP-
negative cases are indicated by black lines in each Kaplan-Meier survival
curve.
(C) Stability of G-CIMP over time in glioma patients. Fifteen samples from
newly diagnosed tumors were tested for G-CIMP positivity with the eight-
marker MethyLight panel. Eight tumors were classified as G-CIMP-positive
(upper left), and seven tumors were classified as G-CIMP-negative (non-G-
CIMP, lower left). Samples from a second procedure, ranging from 2–9 years
after the initial resection, were also evaluated for the G-CIMP-positive cases
(upper right), as well as for the non-G-CIMP cases (lower right). Each marker
was coded as red if methylated and green if unmethylated.
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patients who received a second surgical procedure after tumor
recurrence, with time intervals of up to 8 years between initial
and second surgical procedures. We used the eight-gene Meth-
yLight panel to determine their G-CIMP status and found that
eight samples were G-CIMP positive, whereas seven were
G-CIMP negative. Interestingly, among the G-CIMP-positive
cases, 8/8 (100%) recurrent samples retained their G-CIMP-
positive status. Similarly, among seven G-CIMP-negative cases,
all seven remained G-CIMP negative at recurrence, indicating
stability of the G-CIMP phenotype over time (Figure 5C).
DISCUSSION
In this report, we have identified and characterized a distinct
molecular subgroup in human gliomas. Analysis of epigenetic
changes from TCGA samples identified the existence of
a proportion of GBM tumors with highly concordant DNA meth-
ylation of a subset of loci, indicative of a CpG island methylator
phenotype (G-CIMP). G-CIMP-positive samples were associ-
ated with secondary or recurrent (treated) tumors and tightly
associated with IDH1 mutation. G-CIMP tumors also showed
a relative lack of copy-number variation commonly observed
in GBM, including EGFR amplification, chromosome 7 gain,
and chromosome 10 loss. Interestingly, G-CIMP tumors dis-
played copy-number alterations that were also shown in
gliomas with IDH1 mutations in a recent report (Sanson et al.,
2009). Integration of the DNA methylation data with gene
expression data showed that G-CIMP-positive tumors repre-
sent a subset of proneural tumors. G-CIMP-positive tumors
showed a favorable prognosis within GBMs as a whole and
also within the proneural subset, consistent with prior reports
for IDH1 mutant tumors (Parsons et al., 2008; Yan et al.,
2009). Interestingly, of the five discordant cases of G-CIMP-
positive, IDH1-wild-type tumors, two patients survived more
than 5 years after diagnosis, suggesting that G-CIMP-positive
status may confer favorable outcome independent of IDH1
mutation status. However, studies with many more discordant
cases will be needed to carefully dissect the effects of
G-CIMP status versus IDH1 mutation on survival. To a large
extent, the improved prognosis conferred by proneural tumors
(Phillips et al., 2006) can be accounted for by the G-CIMP-posi-
tive subset. These findings indicate that G-CIMP could be use
to further refine the expression-defined groups into an addi-
tional subtype with clinical implications.
G-CIMP is highly associated with IDH1 mutation across all
glioma tumor grades, and the prevalence of both decreases
with increasing tumor grade. Tumor grade is defined by
morphology only and therefore can be heterogeneous with
respect to molecular subtypes. Within grade IV/glioblastoma
tumors are a subset of patients who tend to be younger and
have a relatively favorable prognosis. It is only throughmolecular
characterization with markers such as IDH1 and G-CIMP status
that one could prospectively identify such patients. Conversely,
these markers could also be used to identify patients with
low- and intermediate-grade gliomas who may exhibit unfavor-
able outcome relative to tumor grade.
In the non-TCGA independent validation set examined in this
study, an IDH1 mutation was detected in 40/43 (93%) low- and
expression and DNA methylation alterations of G-CIMP
tumors among lower-grade gliomas will be helpful for better
understanding of the roles of a mutant IDH1 and G-CIMP DNA
methylation on tumor grade and patient survival.
Genomic DNAs from TCGAGBM tumors were isolated by the TCGA Biospeci-
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GBMs. Similarly, we detected nearly 10-foldmore G-CIMP-posi-
tive gliomas in grade II tumors as compared to grade IV GBMs.
The improved survival of G-CIMP gliomas at all tumor grades
suggests that there are molecular features within G-CIMP
gliomas that encourage a less aggressive tumor phenotype.
Consistent with this, we identified G-CIMP-specific DNAmethyl-
ation changes within a broad panel of genes whose expression
was significantly associated with patient outcome. We observed
that this large subset of differentially silenced genes was
involved in specific functional categories, including markers of
mesenchyme, tumor invasion, and extracellular matrix. This
concept builds upon our prior finding of a mesenchymal
subgroup of glioma which shows poor prognosis (Phillips
et al., 2006). According to this model, a lack of methylation of
these genes in G-CIMP-negative tumors would result in a relative
increase in expression of these genes, which in turn would
promote tumor progression and/or lack of response to currently
available treatment modalities. A comparison of the G-CIMP
gene list with prior gene expression analyses (meta-analyses)
suggests that G-CIMP positive tumors may be less aggressive
because of silencing of key mesenchymal genes.
We found that a minority of genes with significant promoter
hypermethylation showed a concomitant significant decrease
in associated gene expression (263/1520, 17%). This is consis-
tent with previous reports, in which we found similarly low
frequencies of inversely correlated promoter hypermethylation
and gene expression (Houshdaran et al., 2010; Pike et al.,
2008). The lack of an inverse relationship between promoter
hypermethylation and gene expression for most genes may be
attributed to several scenarios, including the lack of appropriate
transcription factors for some unmethylated genes and the use
of alternative promoters for some genes with methylated
promoters. Epigenetics controls expression potential, rather
than expression state.
RBP1 and G0S2 are the two genes showing the strongest
evidence for epigenetic silencing in G-CIMP tumors. RBP1 has
been previously reported to be epigenetically silenced in cancer
cell lines and primary tumors, and the association of its encoded
protein with retinoic acid receptors (RARs) has been well charac-
terized (Esteller et al., 2002). G0S2 gene expression is regulated
by retinoic acid (RA) and encodes a protein that promotes
apoptosis in primary cells, suggesting a tumor-suppressor role
(Kitareewan et al., 2008; Welch et al., 2009). The vitamin A
metabolite RA is important for both embryonic and adult growth.
RA has diverse roles involving neuronal development and
differentiation mediated by RARs (reviewed in Malik et al.,
2000). Interestingly, studies in breast cancer cells have shown
that silencing of RBP1 plays an important role in RA signaling
by lowering all-trans-retinoic acid production and loss of RAR
levels and activity mediated by derepression of PI3K/Akt
signaling pathway, leading to loss of cell differentiation and
tumor progression (Farias et al., 2005a; Farias et al., 2005b).
This mechanism may help describe the molecular features of
tumorigenesis in G-CIMP tumors. Thus, dissecting the geneThe highly concerted nature of G-CIMP methylation suggests
that this phenomenon may be caused by a defect in a trans-
acting factor normally involved in the protection of a defined
subset of CpG island promoters from encroaching DNA methyl-
ation. Loss of function of this factor would result in widespread
concerted DNA methylation changes. We propose that tran-
scriptional silencing of some CIMP genes may provide a favor-
able context for the acquisition of specific genetic lesions.
Indeed, we have recently found that IGFBP7 is silenced by
promoter hypermethylation in BRAF mutant CIMP+ colorectal
tumors (Hinoue et al., 2009). Oncogene-induced senescence
by mutant BRAF is known to be mediated by IGFBP7 (Waja-
peyee et al., 2008). Hence, CIMP-mediated inactivation of
IGFBP7 provides a suitable environment for the acquisition of
BRAF mutation. The tight concordance of G-CIMP status with
IDH1 mutation in GBM tumors is very reminiscent of colorectal
CIMP, in which DNA hypermethylation is strongly associated
with BRAFmutation (Weisenberger et al., 2006). We hypothesize
that the transcriptional silencing of as yet unknown G-CIMP
targets may provide an advantageous environment for the
acquisition of IDH1 mutation.
In our integrative analysis of G-CIMP tumors, we observed
upregulation of genes functionally related to cellular metabolic
processes and positive regulation of macromolecules. This
expression profile may reflect a metabolic adjustment to the
proliferative state of the tumor, in conjunction with the gain-of-
function IDH1 mutation (Dang et al., 2009). Such a metabolic
adjustment may be consistent with Warburg’s observation that
proliferating normal and tumor cells require both biomass and
energy production and convert glucose primarily to lactate,
regardless of oxygen levels, whereas nonproliferating differenti-
ated cells emphasize efficient energy production (reviewed in
Vander Heiden et al., 2009).
In summary, our data indicate that G-CIMP status stratify
gliomas into two distinct subgroups with different molecular
and clinical phenotypes. These molecular classifications have
implications for differential therapeutic strategies for glioma
patients. Further observation and characterization of molecular
subsets will probably provide additional information enabling
insights into the the development and progression of glioma,
and may lead to targeted drug treatment for patients with these
tumors.
EXPERIMENTAL PROCEDURES
Samples and DNA Methylation Assaysmen Core Resource (BCR) and delivered to USC as previously described (The
Cancer Genome Atlas Research Network, 2008). One sample (TCGA-06-0178)
with a confirmed IDH1 mutation was removed from our analyses, given that it
became clear that an incorrect tissue type had been shipped for the DNA
methylation analysis. Four brain genomic DNA samples from apparently
healthy individuals were included as controls. All tissue samples (patients
and healthy individuals) were obtained with institutional review board-
approved protocols from University of Southern California (TCGA GBM
samples), Johns Hopkins School of Medicine (normal brain samples), and
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The University of Texas MD Anderson Cancer Center (glioma validation
samples). Tissue samples were deidentified so that patient confidentiality
was ensured. Genomic DNA methylated in vitro with M.SssI methylase or
whole-genome amplified (WGA) as positive and negative controls for DNA
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, three tables, Supplemental
Experimental Procedures, and a list of authors and affiliations of the TCGA
Cancer Cell
CpG Island Methylator Phenotype in Gliomasmethylation, respectively, were also included. Details are in the Supplemental
Information.
The GoldenGate assays were performed according to the manufacturer’s
instructions and as described previously (Bibikova et al., 2006). The Golden-
Gate methylation assays survey the DNA methylation of up to 1536 CpG
sites—a total of 1505 CpGs spanning 807 unique gene loci are interrogated
in the OMA-002 probe set (Bibikova et al., 2006), and 1498 CpGs spanning
the same number of unique gene regions are investigated in the OMA-003
probe set (The Cancer Genome Atlas Research Network, 2008).
The Infinium methylation assays were performed in accordance with the
manufacturer’s instructions. The assay generates DNA methylation data for
27,578 CpG dinucleotides spanning 14,473 well-annotated, unique gene
promoter and/or 50 gene regions (from1,500 to +1,500 from the transcription
start site). The assay information is available at www.illumina.com and
the probe information is available on the TCGA Data Portal website. Data
from 91 TCGA GBM samples (batches 1, 2, 3, and 10) were included in this
analysis. Batches 1–3 (63 samples) were run on both Inifium and GoldenGate,
whereas batches 4–8 (182 samples) were analyzed exclusively on Golden-
Gate, and batch 10 (28 samples) was analyzed exclusively on Infinium. All
data were packaged and deposited onto the TCGA Data Portal website
(http://tcga.cancer.gov/dataportal). Figure S1C illustrates a Venn diagram
with the overlapping samples between different DNA methylation platforms.
Additional details on DNA methylation detection protocols and TCGA GBM
data archived versions are in the Supplemental Information.
Integrative TCGA Data Platforms
Although ancillary data (expression, mutation, and copy number) were avail-
able for additional tumor samples, we only included those samples for which
there were DNA methylation profiling (either GoldenGate or Infinium). Given
that the Agilent gene expression platform contained a greater number of genes
for which DNAmethylation data were available, we limited our primary analysis
to only the Agilent gene expression data set. Where appropriate, we confirmed
results using the Affymetrix gene expression data. Additional details are in the
Supplemental Information.
Clustering Analysis and Measurement of Differential DNA
Methylation and Differential Gene Expression
Probes for each platform were filtered by removal of those targeting the X and
Y chromosomes, those containing a single-nucleotide polymorphism (SNP)
within five base pairs of the targeted CpG site, and probes containing repeat
element sequences R10 base pairs. We next retained the most variably
methylated probes (standard deviation > 0.20) across the tumor set in each
DNA methylation platform. These final data matrices were used for unsuper-
vised Consensus/Hierarchical clustering analyses. A nonparametric approach
(Wilcoxon rank-sum test) was used for determining probes/genes that are
differentially DNA methylated or differentially expressed between the two
groups of interest. Additional information is described in the Supplemental
Information.
G-CIMP Validation with MethyLight Technology
Tumor samples were reviewed by a neuropathologist (K.A.) to ensure accuracy
of diagnosis as well as quality control tominimize normal tissue contamination.
MethyLight real-time PCR strategy was performed as described previously
(Eads et al., 2000; Eads et al., 1999). Additional details are in the Supplemental
Information.
Pathway and Meta-analyses and Statistical Analyses
Additional tools included the Molecular Signatures Database (MSigDB data-
base v2.5), Database for Annotation, Visualization, and Integrated Discovery
(DAVID) and NextBio. All statistical tests were done with R software (R version
2.9.2, 2009-08-24, (R Development Core Team, 2009) and packages in Bio-
conductor (Gentleman et al., 2004), except as noted. Additional details are
in the Supplemental Information.
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